Shopping Cart
Remove All
Your shopping cart is currently empty
Cendakimab (Synonyms: RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308)
Catalog No. T76942 Copy Product Info
🥰Excellent
Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.
Cendakimab
Copy Product Info🥰Excellent
Catalog No. T76942
Synonyms RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308
Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.
Cendakimab
Cas No. 2151032-62-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | In Stock | In Stock | |
| 5 mg | $463 | In Stock | In Stock | |
| 10 mg | $742 | - | In Stock | |
| 25 mg | $1,120 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis. |
| Targets&IC50 | IL-13α2:631 pM, aglycosylated IL-13:17 pM, IL-13Rα1:352 pM, glycosylated IL-13:37 pM |
| In vitro | Cendakimab is an IgG1k humanized monoclonal antibody that recognizes IL-13 and inhibits its binding to IL-13 receptor-specific subtypes (IL-13-Rα1 and IL-13-Rα2) with an IC50 of 352 pM and 631 pM, respectively, as determined by ELISA. [2] cendakimab inhibited glycosylated and non-glycosylated IL-13-induced STAT6 activity in a dose-dependent manner with IC50 of 37pM and 17pM, respectively. [1] |
| In vivo | In a mouse model of asthma, Cendakimab dose-dependent inhibited AHR (maximum inhibition 70.5%) and IL-13-dependent gene expression, and maximal inhibition of Muc5ac and AMCase activity was 70.7% and 54.2%, respectively. [2] |
| Synonyms | RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308 |
| Reactivity | Human |
| Verified Activity | Immobilized Human IL-13 Protein (His) at 2 μg/mL (30 μL/well) can bind Cendakimab. The EC50 is 0.002081μg/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-13 |
| Molecular Weight | 146.44 kDa |
| Cas No. | 2151032-62-9 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Cendakimab | purchase Cendakimab | Cendakimab cost | order Cendakimab | Cendakimab in vivo | Cendakimab in vitro | Cendakimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.